.AAV9-induced Complement Activation ELISA
AAV9COMPLRUO
The AAV9-Induced Complement Activation ELISA is a Research Use Only (RUO) immunoassay developed to evaluate and characterize complement activation induced by adeno-associated virus 9 (AAV9) vectors in vitro.
AAV9-induced Complement Activation ELISA is a solid-phase enzyme immunoassay for evaluating complement activation triggered by AAV9 vectors.
This assay supports an expanded risk assessment profile of AAV gene therapy candidates, by specifically evaluating complement activation irrespective of the complement pathway (classical, lectin, and alternative) and sample-to-sample variability in a human-serum functional assay.
The AAV9-induced Complement Activation ELISA provides an ability to assess propensity to complement activation in subject samples in vitro. AAV9 particles are immobilized on a microtiter plate, enabling comprehensive capture of the entire process of AAV9-mediated complement activation, where complement activation is assessed via detection of deposited terminal complement complex (TCC). This includes interactions between AAV9 and anti-AAV9 reactive components, as well as the complement system, all within a single well from initiation to readout.
- Reliable, objective, and easy-to-interpret results
- Results in just a few hours
- Low inter-assay & intra-variability, demonstrating good reproducibility
- Developed by our in-house experts to meet customer needs
- Ready-to-use reagents for a streamlined workflow
- Excellent specificity means clear results without false positives
Ota yhteyttä ja kysy lisää: Pia Lindström, p. 020 741 3183, pia.lindstrom@labnet.fi
